Marta Caro

Marta Caro

Auto-generated profile, based on publicly available information

Marta Caro

Department of Immunology and Cell Biology Institute of Parasitology and Biomedicine Lopez‐Neyra Granada Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EBEfres Belmonte-Reche
Efres Belmonte-Reche
PPPablo Peñalver
Pablo Peñalver
MCMarta Caro-Moreno
Marta Caro-Moreno
MMMaría Luisa Mateos-Martín
María Luisa Mateos-Martín
NANorma Adán
Norma Adán
JMJuan Carlos Morales
Juan Carlos Morales
Natural phenolic compounds found in food have demonstrated interesting preventive and therapeutic effects on a large variety of pathologies. Indeed, some of them, such as resveratrol (RES), have been examined in clinical trials. Nevertheless, their success has been scarce mainly due to their low bioavailability. In this study, we found serendipitously that O-silyl RES derivatives exerted a better neuroprotective activity than resveratrol itself and decided to explore them as potential drugs for neurodegenerative and neurological diseases. We have also designed and prepared a series of O-silyl RES prodrugs to improve their bioavailability. We found that di-triethylsilyl and di-triisopropylsilyl RES derivatives were better in vitro neuroprotective and anti-inflammatory agents than RES. Among these derivatives and their corresponding acyl-, glycosyl- and carbamoyl-prodrugs, 3,5-triethylsilyl-4'-(6″-octanoylglucopyranosyl) resveratrol 26 showed the best profile on toxicity and neuroprotective activity in zebra fish embryo. Compound 26 was also capable of reducing the loss of motor coordination in a 3-nitropropionic acid mice model of Huntington's disease, in a similar way to RES. However, 26 diminished pro-inflammatory cytokine IL-6 to a higher extent than RES and improved the latency to fall in the rotarod test by 10% with respect to RES. Finally, we investigated 26 and RES as potential treatments on an experimental autoimmune encephalomyelitis (EAE) multiple sclerosis mice model. We observed that, in a therapeutic regimen, 26 significantly diminished the progression of EAE severity and reduced the percentage of animals with moderate to severe clinical score, whereas RES showed no improvement.

24 November 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
RBRaquel Benitez
Raquel Benitez
MCMarta Caro
Marta Caro
Eduardo Andrés-LeónEduardo Andrés-León
Eduardo Andrés-León
FRFrancisco Javier O'Valle Ravassa
Francisco Javier O'Valle Ravassa
MDMario Delgado
Mario Delgado

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
JGJulia Castillo González
Julia Castillo González
LBLara Buscemi
Lara Buscemi
IMIgnacio Serrano Martínez
Ignacio Serrano Martínez
ILIrene Forte Lago
Irene Forte Lago
MCMarta Caro
Marta Caro
EGElena Gonzalez-Rey
Elena Gonzalez-Rey